You are here: Industry Insights > Merck

News List

Merck and IFEZ ink MoU for expanding investment biospectrumasia
January 24, 2018
The agreement was made between Merck Korea Managing Director Glenn Young and IFEZ Commissioner Kim Jin-yong, under which Merck will invest 22.1 billion won ($20.5 million) in the cluster.
Merck's Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial biospace
January 17, 2018
Merck’s Keytruda has done it again...
FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer biospace
January 15, 2018
AstraZeneca and Merck today announced that the FDA has approved LYNPARZA® (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)
Nestle reportedly pulls out in front to buy Merck KGaA consumer health unit with $5 billion bid pharmafile
January 12, 2018
It has been reported that Swiss food giant Nestle has pulled out in front as the top bidder for Merck KGaA’s consumer health business, allegedly offering up to $5 billion.
Nestle Emerges as the Frontrunner for Merck KGaA's $5B Consumer Health Biz biospace
January 11, 2018
Nestle is the frontrunner to buy Merck KGaA’s consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.
FDA Slaps Breakthrough Tag on Eisai, Merck's Combo Renal Cell Carcinoma Drug biospace
January 10, 2018
Merck and development partner Eisai Co., Ltd. snagged Breakthrough Therapy Designation from the FDA for the combination treatment the companies are developing for the potential treatment of patients with advanced and/or metastatic renal cell carcinoma
Merck to work with bluebird bio on viral vector manufacturing pharmaasia
January 04, 2018
Merck aims to accelerate its manufacturing of new treatments for a broad range of serious diseases via this collaboration.
US green light for Pfizer/Merck diabetes therapies pharmatimes
January 03, 2018
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA americanpharmaceuticalreview
December 27, 2017
Merck KGaA announced the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA (axitinib) for treatment-naïve patients with advanced renal cell carcinoma (RCC).
WuXi, Merck to launch biotech incubator biospectrumasia
December 27, 2017
The incubator Explore Bio will be located at Merck Serono’s existing complex in Yavne, a town in central Israel.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page